Rhumbline Advisers Ionis Pharmaceuticals Inc Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

A detailed history of Rhumbline Advisers transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Rhumbline Advisers holds 196,942 shares of IONS stock, worth $6.83 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

196,942

Previous 178,089 10.59%

Holding current value

$6.83 Million

Previous $8.49 Million 7.05%

% of portfolio

0.01%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$40.06 - $51.86 $755,251 - $977,716	18,853 Added 10.59%	196,942 $7.89 Million
Q2 2024 Aug 01, 2024	SELL	$36.45 - $47.7 $48,478 - $63,441	-1,330 Reduced 0.74%	178,089 $8.49 Million
Q1 2024 May 09, 2024	SELL	$42.03 - $53.55 $840,473 - $1.07 Million	-19,997 Reduced 10.03%	179,419 $7.78 Million
Q4 2023 Feb 08, 2024	BUY	$43.39 - $51.63 $84,870 - $100,988	1,956 Added 0.99%	199,416 $10.1 Million
Q3 2023 Nov 09, 2023	BUY	$38.5 - $47.13 $4,889 - $5,985	127 Added 0.06%	197,460 $8.96 Million
Q2 2023 Aug 08, 2023	BUY	$34.73 - $43.33 $717,105 - $894,677	20,648 Added 11.69%	197,333 $8.1 Million
Q1 2023 May 11, 2023	BUY	$33.58 - $41.2 $386,908 - $474,706	11,522 Added 6.98%	176,685 $6.32 Million
Q4 2022 Feb 14, 2023	BUY	$37.12 - $46.52 $350,746 - $439,567	9,449 Added 6.07%	165,163 $6.24 Million
Q3 2022 Nov 10, 2022	BUY	$36.54 - $48.66 $44,286 - $58,975	1,212 Added 0.78%	155,714 $6.89 Million
Q2 2022 Aug 11, 2022	BUY	$31.71 - $43.0 $664,070 - $900,506	20,942 Added 15.68%	154,502 $5.72 Million
Q1 2022 May 12, 2022	SELL	$29.88 - $37.04 $184,927 - $229,240	-6,189 Reduced 4.43%	133,560 $4.95 Million
Q4 2021 Feb 10, 2022	BUY	$25.61 - $35.1 $35,495 - $48,648	1,386 Added 1.0%	139,749 $4.25 Million
Q3 2021 Nov 12, 2021	SELL	$33.54 - $40.55 $40,985 - $49,552	-1,222 Reduced 0.88%	138,363 $4.64 Million
Q2 2021 Aug 05, 2021	SELL	$34.54 - $47.25 $166,517 - $227,792	-4,821 Reduced 3.34%	139,585 $5.57 Million
Q1 2021 May 06, 2021	SELL	$42.51 - $63.78 $314,786 - $472,290	-7,405 Reduced 4.88%	144,406 $6.49 Million
Q4 2020 Feb 10, 2021	SELL	$45.3 - $60.27 $119,320 - $158,751	-2,634 Reduced 1.71%	151,811 $8.58 Million
Q3 2020 Nov 12, 2020	SELL	$47.45 - $62.95 $254,332 - $337,412	-5,360 Reduced 3.35%	154,445 $7.33 Million
Q2 2020 Aug 13, 2020	BUY	$46.85 - $61.05 $953,584 - $1.24 Million	20,354 Added 14.6%	159,805 $9.42 Million
Q1 2020 May 06, 2020	SELL	$41.6 - $63.4 $76,252 - $116,212	-1,833 Reduced 1.3%	139,451 $6.59 Million
Q4 2019 Feb 05, 2020	BUY	$53.85 - $65.27 $184,328 - $223,419	3,423 Added 2.48%	141,284 $8.54 Million
Q3 2019 Oct 23, 2019	SELL	$59.06 - $72.15 $48,547 - $59,307	-822 Reduced 0.59%	137,861 $8.26 Million
Q2 2019 Aug 14, 2019	SELL	$62.09 - $86.14 $142,807 - $198,122	-2,300 Reduced 1.63%	138,683 $8.91 Million
Q1 2019 May 01, 2019	SELL	$52.92 - $81.17 $41,965 - $64,367	-793 Reduced 0.56%	140,983 $11.4 Million
Q4 2018 Jan 31, 2019	SELL	$43.37 - $59.54 $231,465 - $317,764	-5,337 Reduced 3.63%	141,776 $7.66 Million
Q3 2018 Nov 07, 2018	SELL	$42.88 - $53.7 $117,191 - $146,762	-2,733 Reduced 1.82%	147,113 $7.59 Million
Q2 2018 Aug 06, 2018	BUY	$40.53 - $50.7 $101,811 - $127,358	2,512 Added 1.7%	149,846 $6.24 Million
Q1 2018 May 02, 2018	SELL	$44.08 - $55.05 $195,759 - $244,477	-4,441 Reduced 2.93%	147,334 $6.49 Million
Q4 2017 Feb 09, 2018	SELL	$50.3 - $64.39 $116,947 - $149,706	-2,325 Reduced 1.51%	151,775 $7.63 Million
Q3 2017 Nov 06, 2017	BUY	$45.56 - $59.57 $7.02 Million - $9.18 Million	154,100	154,100 $7.81 Million

Others Institutions Holding IONS

# of Institutions

402

Shares Held

136M

Call Options Held

862K

Put Options Held

582K

View Full List

About IONIS PHARMACEUTICALS INC

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $4.92B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

More about IONS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Ionis Pharmaceuticals Inc Transaction History